Note 10 - License, Research and Collaboration Agreements	9 Months Ended
Sep. 30, 2022
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	10. License, Research and Collaboration Agreements Collaboration Agreements *ABL Bio Corporation ("ABL Bio") Agreement* In November 2018, the Company's wholly-owned subsidiary, TRIGR, and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement (the “TRIGR License Agreement”) which granted TRIGR a license to ABL001, ABL Bio’s bispecific antibody targeting DLL4 and VEGF-A (renamed CTX-009). Under the terms of the agreement, ABL Bio and TRIGR would jointly develop CTX-009, with ABL Bio responsible for development of CTX-009 throughout the end of Phase 1 clinical trials and TRIGR responsible for the development of CTX-009 from Phase 2 and onward. ABL Bio received a $5 million upfront payment, a $6 million development milestone for the completion of Phase 1 clinical trials and is eligible to receive a total of up to $110 million of development and regulatory milestone payments, up to $295 million of commercial milestone payments and tiered single-digit royalties on net sales of CTX-009 in Oncology. As a result of the TRIGR acquisition in 2021, the TRIGR License Agreement was assigned to the Company and the Company has assumed all the rights and liabilities of the agreement. *Adimab Agreement* The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale. There were no milestone payments made during the first nine months of 2022. As of September 30, 2022, future potential milestone payments in connection with this agreement amounted to $2.0 million. Other License and Research Agreements *FUJIFILM Diosynth Biotechnologies ("Fujifilm”) Agreement* The Company entered into a scope of work (“SOW”) under a master services agreement with Fujifilm on July 20, 2020. The Company made no cash payments and recorded $89 thousand in research and development expense during the three months ended September 30, 2022 related to this agreement. The Company made cash payments of $0.5 million and recorded $2.9 million in research and development expense during the nine months ended September 30, 2022. As of September 30, 2022, future payments in connection with the SOW amounted to approximately $0.6 million and future expenses amounted to less than $100 thousand.

Note 10 - License, Research and Collaboration Agreements

9 Months Ended

Sep. 30, 2022

Collaborative Arrangement Disclosure [Text Block]

10. License, Research and Collaboration Agreements

Collaboration Agreements

ABL Bio Corporation ("ABL Bio") Agreement

In November 2018, the Company's wholly-owned subsidiary, TRIGR, and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement (the “TRIGR License Agreement”) which granted TRIGR a license to ABL001, ABL Bio’s bispecific antibody targeting DLL4 and VEGF-A (renamed CTX-009). Under the terms of the agreement, ABL Bio and TRIGR would jointly develop CTX-009, with ABL Bio responsible for development of CTX-009 throughout the end of Phase 1 clinical trials and TRIGR responsible for the development of CTX-009 from Phase 2 and onward. ABL Bio received a $5 million upfront payment, a $6 million development milestone for the completion of Phase 1 clinical trials and is eligible to receive a total of up to $110 million of development and regulatory milestone payments, up to $295 million of commercial milestone payments and tiered single-digit royalties on net sales of CTX-009 in Oncology. As a result of the TRIGR acquisition in 2021, the TRIGR License Agreement was assigned to the Company and the Company has assumed all the rights and liabilities of the agreement.

Adimab Agreement

The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale. There were no milestone payments made during the first nine months of 2022. As of September 30, 2022, future potential milestone payments in connection with this agreement amounted to $2.0 million.

Other License and Research Agreements

FUJIFILM Diosynth Biotechnologies ("Fujifilm”) Agreement

The Company entered into a scope of work (“SOW”) under a master services agreement with Fujifilm on July 20, 2020. The Company made no cash payments and recorded $89 thousand in research and development expense during the three months ended September 30, 2022 related to this agreement. The Company made cash payments of $0.5 million and recorded $2.9 million in research and development expense during the nine months ended September 30, 2022. As of September 30, 2022, future payments in connection with the SOW amounted to approximately $0.6 million and future expenses amounted to less than $100 thousand.